Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Oct 9:7:353-9.
doi: 10.2147/IJNRD.S61895. eCollection 2014.

Switch from epoetin to darbepoetin alfa in hemodialysis: dose equivalence and hemoglobin stability

Javier Arrieta  1 , Iñigo Moina  1 , José Molina  2 , Isabel Gallardo  3 , María Luisa Muñiz  4 , Carmen Robledo  5 , Oscar García  5 , Fernando Vidaur  6 , Rosa Inés Muñoz  3 , Izaskun Iribar  7 , Román Aguirre  7 , Antonio Maza  8
Affiliations

Switch from epoetin to darbepoetin alfa in hemodialysis: dose equivalence and hemoglobin stability

Javier Arrieta et al. Int J Nephrol Renovasc Dis. .

Abstract

Aim: The objective of the study reported here was to describe dose equivalence and hemoglobin (Hb) stability in a cohort of unselected hemodialysis patients who were switched simultaneously from epoetin alfa to darbepoetin alfa.

Methods: This was a multicenter, observational, retrospective study in patients aged ≥18 years who switched from intravenous (IV) epoetin alfa to IV darbepoetin alfa in October 2007 (Month 0) and continued on hemodialysis for at least 24 months. The dose was adjusted to maintain Hb within 1.0 g/dL of baseline.

Results: We included 125 patients (59.7% male, mean [standard deviation (SD)] age 70.4 [13.4] years). No significant changes were observed in Hb levels (mean [SD] 11.9 [1.3] g/dL, 12.0 [1.5], 12.0 [1.5], and 12.0 [1.7] at Months -12, 0, 12 and 24, respectively, P=0.409). After conversion, the erythropoiesis-stimulating agent (ESA) dose decreased significantly (P<0.0001), with an annual mean of 174.7 (88.7) international units (IU)/kg/week for epoetin versus 95.7 (43.4) (first year) and 91.4 (42.7) IU/kg/week (second year) for darbepoetin (65% and 64% reduction, respectively). The ESA resistance index decreased from 15.1 (8.5) IU/kg/week/g/dL with epoetin to 8.1 (3.9) (first year) and 7.9 (4.0) (second year) with darbepoetin (P<0.0001). The conversion rate was 354:1 in patients requiring high (>200 IU/kg/week) doses of epoetin and 291:1 in patients requiring low doses.

Conclusion: In patients on hemodialysis receiving ESAs, conversion from epoetin alfa to darbepoetin alfa was associated with an approximate and persistent reduction of 65% of the required dose. To maintain Hb stability, a conversion rate of 300:1 seems to be appropriate for most patients receiving low doses of epoetin alfa (≤200 IU/kg/week), while 350:1 would be better for patients receiving higher doses.

Keywords: chronic kidney disease; darbepoetin alfa; dose equivalence; epoetin alfa; hemodialysis; hemoglobin.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Changes in hemoglobin levels over time. Abbreviation: SD, standard deviation.
Figure 2
Figure 2
Changes in erythropoiesis-stimulating agent (ESA) dose over time. Note: Darbepoetin doses were converted at a 1:200 conversion rate. Abbreviation: SD, standard deviation.
Figure 3
Figure 3
Changes in erythropoiesis-stimulating agent (ESA) resistance index over time. Abbreviation: SD, standard deviation.
See this image and copyright information in PMC

References

    1. Macdougall IC. Optimizing the use of erythropoietic agents – pharmacokinetic and pharmacodynamic considerations. Nephrol Dial Transplant. 2002;17(Suppl 5):66–70. - PubMed
    1. Locatelli F, Aljama P, Bárány P, et al. European Best Practice Guidelines Working Group Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant. 2004;19(Suppl 2):ii1–ii47. - PubMed
    1. Nissenson AR, Swan SK, Lindberg JS, et al. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. Am J Kidney Dis. 2002;40(1):110–118. - PubMed
    1. Fishbane S. The role of erythropoiesis-stimulating agents in the treatment of anemia. Am J Manag Care. 2010;16(Suppl Issues):S67–S73. - PubMed
    1. McGowan T, Vaccaro NM, Beaver JS, Massarella J, Wolfson M. Pharmacokinetic and pharmacodynamic profiles of extended dosing of epoetin alfa in anemic patients who have chronic kidney disease and are not on dialysis. Clin J Am Soc Nephrol. 2008;3(4):1006–1014. - PMC - PubMed

LinkOut - more resources